IDEXX Laboratories opens the week with a clear consensus, NASDAQ-100 shares in a steady trend

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-28, 09:39.

IDEXX Laboratories (US45168D1046) starts the week with a defined analyst consensus and a NASDAQ-100 listing that keeps the stock firmly in the large-cap US health-sector universe, with several houses updating views over recent months according to MarketScreener data. Analysts broadly maintain constructive coverage, reflected in a majority of positive ratings and stable targets anchored around the current trading range.

How analysts rate IDEXX

On MarketScreener, IDEXX Laboratories is covered by more than ten research houses, with a majority of recommendations in the Buy or Outperform camp and only a minority at Hold, underscoring a broadly supportive stance from the sell-side community. The consensus 12-month target price sits moderately above recent trading levels, signalling expectations for mid-single-digit percentage upside rather than aggressive re-rating, based on the compiled estimates.

FactSet data referenced by several market-commentary outlets show that analysts project steady revenue growth in the high-single-digit range and EBITDA margin stability in upcoming quarters, aligning with the company’s recent historical performance trajectory. According to a recent InsiderMonkey analysis on IDEXX, the company’s diagnostic focus and recurring revenue streams underpin many of these constructive assumptions.

Consensus expectations and valuation

For the current fiscal year, analyst models clustered on MarketScreener point to revenue above 4 billion US dollars and continued earnings-per-share growth in the low-teens percentage range, supported by expanding global demand for veterinary diagnostics and practice-management solutions. The resulting valuation places IDEXX at a premium price-to-earnings multiple versus several healthcare peers, a premium that analysts justify with its strong recurring-revenue profile and dominant position in companion-animal diagnostics, as highlighted in recent commentary from US brokers.

In sector comparisons, IDEXX frequently appears alongside names such as Zoetis and Thermo Fisher Scientific, where investors weigh growth, margins and defensiveness within the broader healthcare and life-sciences complex, according to a Reuters overview of US healthcare diagnostics stocks. Across that peer group, IDEXX’s profit growth trajectory is described as robust rather than spectacular, which fits the current consensus tone of steady compounding.

The business behind the stock

IDEXX Laboratories generates most of its revenue from veterinary diagnostic instruments and consumables, including its Catalyst chemistry analyzers and SNAP test kits that support blood and urine analysis in companion-animal clinics worldwide, as described on its corporate site. The company complements these hardware and reagent sales with cloud-based practice-management software, reference-laboratory services and imaging solutions, creating a recurring-revenue ecosystem around animal health diagnostics.

Where the shares trade today

The IDEXX Laboratories shares (US45168D1046) trade on NASDAQ at 516.00 US dollars as of 2026-06-26, 20:00, based on recent quote data from finanzen100.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or a solicitation of any kind. All data are based on publicly available sources believed to be reliable but cannot be guaranteed. Investors should conduct their own research or consult a licensed financial advisor before making investment decisions.